| Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro J Visser, A van Boxel-Dezaire, D Methorst, T Brunt, ER De Kloet, ... Blood, The Journal of the American Society of Hematology 91 (11), 4255-4264, 1998 | 262 | 1998 |
| Instability of the ecstasy market and a new kid on the block: mephedrone TM Brunt, A Poortman, RJM Niesink, W van den Brink Journal of psychopharmacology 25 (11), 1543-1547, 2011 | 251 | 2011 |
| The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects J Van Amsterdam, T Brunt, W van den Brink Journal of psychopharmacology 29 (3), 254-263, 2015 | 200 | 2015 |
| Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project TM Brunt, C Nagy, A Bücheli, D Martins, M Ugarte, C Beduwe, ... Drug testing and analysis 9 (2), 188-198, 2017 | 170 | 2017 |
| A Pro51Ser mutation in the COCH gene is associated with late onset autosomal dominant progressive sensorineural hearing loss with vestibular defects YJM de Kok, SJH Bom, TM Brunt, MH Kemperman, E van Beusekom, ... Human molecular genetics 8 (2), 361-366, 1999 | 165 | 1999 |
| Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study P van der Pol, N Liebregts, T Brunt, J van Amsterdam, R de Graaf, DJ Korf, ... Addiction 109 (7), 1101-1109, 2014 | 133 | 2014 |
| An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants TM Brunt, S Rigter, J Hoek, N Vogels, P Van Dijk, RJM Niesink Addiction 104 (5), 798-805, 2009 | 126 | 2009 |
| Potency trends of Δ9‐tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15 RJM Niesink, S Rigter, MW Koeter, TM Brunt Addiction 110 (12), 1941-1950, 2015 | 123 | 2015 |
| Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre L Hondebrink, JJ Nugteren-van Lonkhuyzen, D Van Der Gouwe, TM Brunt Drug and alcohol dependence 147, 109-115, 2015 | 118 | 2015 |
| Content of ecstasy in the Netherlands: 1993–2008 N Vogels, TM Brunt, S Rigter, P Van Dijk, H Vervaeke, RJM Niesink Addiction 104 (12), 2057-2066, 2009 | 110 | 2009 |
| Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users TM Brunt, MW Koeter, RJM Niesink, W van den Brink Psychopharmacology 220, 751-762, 2012 | 100 | 2012 |
| The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison TM Brunt, RJM Niesink Drug testing and analysis 3 (9), 621-634, 2011 | 99 | 2011 |
| Drug checking as a harm reduction tool for recreational drug users: opportunities and challenges T Brunt European Monitoring Centre for Drugs and Drug Addiction, 2017 | 87 | 2017 |
| Polymorphic detection of a parthenogenetic maternal and double paternal contribution to a 46, XX/46, XY hermaphrodite JC Giltay, T Brunt, FA Beemer, JM Wit, HKP Van Amstel, PL Pearson, ... The American Journal of Human Genetics 62 (4), 937-940, 1998 | 86 | 1998 |
| Adverse effects of levamisole in cocaine users: a review and risk assessment TM Brunt, J van den Berg, E Pennings, B Venhuis Archives of Toxicology 91, 2303-2313, 2017 | 75 | 2017 |
| Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis TM Brunt, M van Genugten, K Höner-Snoeken, MJ van de Velde, ... Journal of clinical psychopharmacology 34 (3), 344-349, 2014 | 74 | 2014 |
| Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases RPW Litjens, TM Brunt, GJ Alderliefste, RHS Westerink European Neuropsychopharmacology 24 (8), 1309-1323, 2014 | 73 | 2014 |
| Purity, adulteration and price of drugs bought on‐line versus off‐line in the Netherlands D van der Gouwe, TM Brunt, M van Laar, P van der Pol Addiction 112 (4), 640-648, 2017 | 67 | 2017 |
| mCPP: an undesired addition to the ecstasy market MG Bossong, TM Brunt, JP Van Dijk, SM Rigter, J Hoek, HMJ Goldschmidt, ... Journal of Psychopharmacology 24 (9), 1395-1401, 2010 | 66 | 2010 |
| GHB, GBL and 1, 4-BD Addiction T M Brunt, J GC van Amsterdam, W van den Brink Current Pharmaceutical Design 20 (25), 4076-4085, 2014 | 57 | 2014 |
Laura HondebrinkDutch Poisons Information CenterVerified email at umcutrecht.nl
